TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03473275

Intervention type: DIAGNOSTIC_TEST
Intervention: Cold Pressor test
Description: Both feet in icy waterbath alternated with body temperature water

Intervention type: DIAGNOSTIC_TEST
Intervention: Cold Pressor test
Description: Both feet in icy waterbath alternated with body temperature water

Intervention type: DIAGNOSTIC_TEST
Intervention: Cold Pressor test
Description: Both feet in icy waterbath alternated with body temperature water

Intervention type: DIAGNOSTIC_TEST
Intervention: Cold Pressor test
Description: Both feet in icy waterbath alternated with body temperature water

Intervention type: DIAGNOSTIC_TEST
Intervention: PinPrick test
Description: Pricking both feet with a needle using gravity (without penetrating) alternated with cotton swap
Study: NCT03385447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participants underwent 12-weeks of exercise prescription aimed at the federal guidelines (3 days/week).
Study: NCT06212596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumour suppressor proteins (TSPs). Selinexor is an oral, first-in-class, potent, slowly reversible, covalent-binding Selective Inhibitor of Nuclear Export (SINE) compound that specifically blocks the karyopherin protein Exportin 1 (XPO1), also called chromosome region maintenance 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a long used conventional chemotherapy with potent anti-myeloma activity and low toxicity when administered at low doses as in the current protocol (Hajek et al. (2016)). It is being extensively used in combination with novel agents, including bortezomib, lenalidomide, and pomalidomide, and provides a cost-effective and well-tolerated alternative as a combination partner (Morgan et al. (2007); Mai et al. (2015); Baz et al. (2016)).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a long used conventional chemotherapy with potent anti-myeloma activity and low toxicity when administered at low doses as in the current protocol (Hajek et al. (2016)). It is being extensively used in combination with novel agents, including bortezomib, lenalidomide, and pomalidomide, and provides a cost-effective and well-tolerated alternative as a combination partner (Morgan et al. (2007); Mai et al. (2015); Baz et al. (2016)).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Steroids have been a very effective backbone for every myeloma combination therapy developed so far. Prednisone is the standard steroid in a number of widely used regimens (Mateos et al. (2010);Palumbo et al. (2006)). Decreasing the morbidity associated with high dose steroid use by using better-tolerated regimens addresses a large unmet need of the myeloma patient population.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Steroids have been a very effective backbone for every myeloma combination therapy developed so far. Prednisone is the standard steroid in a number of widely used regimens (Mateos et al. (2010);Palumbo et al. (2006)). Decreasing the morbidity associated with high dose steroid use by using better-tolerated regimens addresses a large unmet need of the myeloma patient population.
Study: NCT02923349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01949
Description: Initial cohort dose of INCAGN01949 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
Study: NCT03187704

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HEPA air filtration
Description: Air filters were placed in participant homes

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: HEPA air filtration
Description: Air filters were placed in participant homes
Study: NCT01653925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention first
Description: The dietary intervention will be aimed to increase intake of ω-3 long chain fatty acids and to reduce intake of saturated and trans fatty acids. Three consultations with a nutritionist experienced in clinical trials will be planned over a 6-month period. An additional 2 consultations in the last 6 months with the study nutritionist will be planned for men allocated to the dietary fat intervention arm first. Then, after the 6 months of diet intervention, drug intervention with 5α-Reductase Inhibitor will be add to diet for the 6 following months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug (Dutasteride) intervention first
Description: 5α-Reductase Inhibitor will be taken daily in tablet dosage form (0.5 mg) taken orally for 12 months depend of the group. After 6 months of drug intake, dietary fat intervention will be add to treatment for the following 6 months. Three consultations with a nutritionist experienced in clinical trials will be planned over this 6-month period.
Study: NCT00886548

Intervention type: PROCEDURE
Intervention: Ultrasound performed
Description: Nurse-driven ultrasound performed
Study: NCT04402125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TargEted MAnageMent Intervention (TEAM)
Description: TEAM targets acquisition of self-management expertise and use of healthy behaviors that are intended to reduce stroke risk and burden. TEAM participants will continue in their regular medical care, supplemented by the TEAM intervention. Components are as follows:~1. A 60 minute initial session in which the nurse and the PED meet with the patient who has experienced stroke or TIA. The initial session will cover introductions, orientation, and logistic planning.~2. Five 60-minute group sessions with 6-10 stroke survivors (and their care partners as applicable) held approximately 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 week after enrollment. Sessions are co-lead by a nurse and a PED.~3. Six brief telephone sessions implemented after the conclusion of the 5 TEAM group sessions. Calls will be conducted every 2 weeks for 12 weeks. Calls will reinforce group session content, provide social support and facilitate linkage with other care providers.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TargEted MAnageMent Intervention (TEAM)
Description: TEAM targets acquisition of self-management expertise and use of healthy behaviors that are intended to reduce stroke risk and burden. TEAM participants will continue in their regular medical care, supplemented by the TEAM intervention. Components are as follows:~1. A 60 minute initial session in which the nurse and the PED meet with the patient who has experienced stroke or TIA. The initial session will cover introductions, orientation, and logistic planning.~2. Five 60-minute group sessions with 6-10 stroke survivors (and their care partners as applicable) held approximately 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 week after enrollment. Sessions are co-lead by a nurse and a PED.~3. Six brief telephone sessions implemented after the conclusion of the 5 TEAM group sessions. Calls will be conducted every 2 weeks for 12 weeks. Calls will reinforce group session content, provide social support and facilitate linkage with other care providers.
Study: NCT01294644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic acid injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic acid injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline placebo for injection
Study: NCT01492127

Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: Blood test
Description: Blood test
Study: NCT03784222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blonanserin
Description: patients were prescribed blonanserin 4-24mg/d according to the patients' response and tolerability

Intervention type: OTHER
Group type: OTHER
Intervention: MRI and serum BDNF
Description: 60 patients receive MRI and serum BDNF test, 60 controls receive MRI, 20 of the 60 controls receive serum BDNF test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI and serum BDNF
Description: 60 patients receive MRI and serum BDNF test, 60 controls receive MRI, 20 of the 60 controls receive serum BDNF test
Study: NCT00835328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin (9-39)
Description: A short-term intravenous infusion of the investigational drug, Exendin (9-39), will be administered over up to 9 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin (9-39)
Description: A short-term intravenous infusion of the investigational drug, Exendin (9-39), will be administered over up to 9 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin (9-39)
Description: A short-term intravenous infusion of the investigational drug, Exendin (9-39), will be administered over up to 9 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin (9-39)
Description: A short-term intravenous infusion of the investigational drug, Exendin (9-39), will be administered over up to 9 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: A short-term intravenous infusion of normal saline (0.9% NaCl), or the vehicle, will be administered over up to 9 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: A short-term intravenous infusion of normal saline (0.9% NaCl), or the vehicle, will be administered over up to 9 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: A short-term intravenous infusion of normal saline (0.9% NaCl), or the vehicle, will be administered over up to 9 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: A short-term intravenous infusion of normal saline (0.9% NaCl), or the vehicle, will be administered over up to 9 hours.
Study: NCT02827110

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fiberoptic bronchoscope
Description: Tracheal intubation using fiberoptic bronchoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fiberoptic bronchoscope
Description: Tracheal intubation using fiberoptic bronchoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pentax-airway scope
Description: Tracheal intubation using pentax-AWS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: semi-rigid collar
Description: semi-rigid collar immobilization of the cervical spine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: semi-rigid collar
Description: semi-rigid collar immobilization of the cervical spine
Study: NCT03130946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo-assisted core needle biopsy
Description: Rotational core needle biopsy would be done under local anesthesia. A small incision would be made in the axilla and core needle biopsy be performed using a special cryo-assisted stick freeze device (Cassi II, Scion Medical Technologies, USA). The cytological and histological specimens would be sent for diagnosis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FNA
Description: FNA would be performed using a 10ml syringe with a 24 gauge needle without anesthesia.
Study: NCT03699774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8500a
Description: DS-8500a is provided as three 25-mg tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin is provided as a 10-mg tablet for oral administration
Study: NCT01609049

Intervention type: DRUG
Intervention: Peginterferon alfa-2a
Description: Administration of treatment will be according to local recommendation under local labeling.

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin tablets twice daily orally will be administered depending on body weight, according summary product characteristics and prescribing of ribavirin in real clinical practice.
Study: NCT02980211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alveolar Ridge Reconstruction
Description: Reconstruction of dehiscence defects in extraction sockets with a minimally invasive technique using a particulate bone allograft and a non-absorbable dense polytetrafluoroethylene (dPTFE) membrane
Study: NCT04322552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib at a dosage of will be administered daily from on D5 through D16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin tablet
Description: Digoxin at a dosage of 0.25mg will be administered at day 1 and day 12
Study: NCT04162873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO or via feeding tube
Study: NCT03130946

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FNA
Description: FNA would be performed using a 10ml syringe with a 24 gauge needle without anesthesia.
Study: NCT00623714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: fluticasone
Description: Two puffs, of 250 µg each, will be administered to each patient to obtain a 500-µg dose at each prespecified time point. A total of five (5) doses (500 µg) each of inhaled fluticasone will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: fluticasone
Description: Two puffs, of 250 µg each, will be administered to each patient to obtain a 500-µg dose at each prespecified time point. A total of five (5) doses (500 µg) each of inhaled fluticasone will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
Study: NCT04162873

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO or via feeding tube

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05070182

Intervention type: DIAGNOSTIC_TEST
Intervention: REE - Resting Energy Expenditure
Description: REEs represent 60-70% of the needs for a sedentary person and 50% of physically active people.~For the measurement of REE will be used the metabolic computer (Medical Graphics, Ultima CCM, Minneapolis, USA), which with continuous recording of breath-to-breath volume (Vt), respiratory rate (RR) of ventilation per minute volume (MV) ), of inhaled and exhaled gases (O2 and CO2) has the ability to calculate the values of VO2, VCO2 and with the help of equations the values of REE and RQ.~All patients in the study will be monitored with the metabolic computer. Their measurements will be recorded every day during their stay in the ICU.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Doppler
Description: The measurement of flow velocities in the middle cerebral artery will be done with the transcranial Doppler using a low frequency (2 MHz) ultrasound head.~All patients entering the study will be examined with the TCD every day during their stay in the ICU.
Study: NCT04584827

Intervention type: OTHER
Intervention: lactate level
Description: Lactate, a byproduct of glycolysis, is an indicator of weak tissue perfusion and a useful biomarker with prognostic value in various diseases. Lactate value is calculated by blood gas.

Intervention type: OTHER
Intervention: lactate level
Description: Lactate, a byproduct of glycolysis, is an indicator of weak tissue perfusion and a useful biomarker with prognostic value in various diseases. Lactate value is calculated by blood gas.

Intervention type: OTHER
Intervention: Glasgow Outcome Scale
Description: Glasgow Outcome Scale; It is a scale developed to categorize people suffering from head trauma or non-traumatic acute brain injury into broad outcome categories. It shows postoperative mortality and morbidity of patients who underwent intracranial surgery.

Intervention type: OTHER
Intervention: Glasgow Outcome Scale
Description: Glasgow Outcome Scale; It is a scale developed to categorize people suffering from head trauma or non-traumatic acute brain injury into broad outcome categories. It shows postoperative mortality and morbidity of patients who underwent intracranial surgery.
Study: NCT01002573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: Ibuprofen, 10 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen
Description: Acetaminophen, 10mg/kg
Study: NCT03196401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: durvalumab 1500mg administered intravenously every 28 days, for a total of six doses

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: concurrent definitive radiation therapy to the bone plasmacytoma initiated within two weeks of starting
Study: NCT03434665

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transradial celiac artery angiography
Description: * After completion of transradial diagnostic coronary angiography and/or PCI, before removal of the radial arterial sheath, selective angiography of the celiac artery will be performed.~* Technically, a 0.35-inch wire is advanced into the descending aorta. A 125 cm 5-French Judkins right catheter is inserted over this wire, which is then removed. The distal tip of the catheter is brought in front of the ostium of the celiac artery and positioning is confirmed with angiography of the celiac artery. Two or three views will be obtained to determine the optimal view to visualize the left gastric artery anatomy. All material is removed and hemostasis is obtained as per clinical routine for coronary angiography.
Study: NCT00920166

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pétunia 1
Description: Infant formula used for non breastfed children

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Regular formula
Description: Infant formula used for non breastfed children
Study: NCT01189201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773/linagliptin
Description: medium single dose of BI 10773/linagliptin FDC (Formulation A1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773/linagliptin
Description: medium single dose of BI 10773/linagliptin FDC (Formulation A3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773/linagliptin SID
Description: medium single dose of mono components BI 10773/linagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773/linagliptin FDC
Description: medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
Study: NCT01379339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 10mg/m2
Description: * Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 12.5mg/m2
Description: * Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 15mg/m2
Description: * Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 17.5mg/m2
Description: * Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20mg/m2
Description: * Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)
Study: NCT00204568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adriamycin
Description: 60 mg/m2, d1, W d22
Study: NCT02355210

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactose powder, 5 grams
Study: NCT00204568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trofosfamide
Description: 300 mg absolute d1-7, followed by 150 mg absolute continuously
Study: NCT04676581

Intervention type: OTHER
Intervention: Leech Therapy
Description: Patient who received leeches (for more than 2 days) at the Amiens University Hospital over a period of 9 years (2010-2018)